A Single-center, Open-label, Fixed-sequence Trial to Investigate the Effect of Multiple-dose Aprocitentan on the Single-dose Pharmacokinetics of Combined Oral Contraceptives in Healthy Female Participants
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Aprocitentan (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Essential hypertension; Hypertension; Resistant hypertension
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 11 Mar 2025 Status changed from not yet recruiting to completed.
- 03 Feb 2025 New trial record